Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 15/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | CDC25A | P30304 | 1/20 | 0.40 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179562 | 0.95 | VDR (0.59) | VDRHDAC3HDAC6HDAC2CDC25A | |
| SCHEMBL13531904 | 0.93 | VDR (0.57) | VDRHDAC3HDAC6HDAC2 | |
| SCHEMBL13531910 | 0.88 | VDR (0.60) | VDRHDAC3HDAC6HDAC2 | |
| SCHEMBL3178247 | 0.86 | VDR (0.54) | VDRHDAC3HDAC6HDAC2 | |
| SCHEMBL12398151 | 0.86 | VDR (0.45) | VDRHDAC3HDAC6HDAC2 | |
| SCHEMBL13531903 | 0.85 | VDR (0.48) | VDRHDAC3HDAC6HDAC2 | |
| SCHEMBL3186188 | 0.85 | VDR (0.51) | VDRHDAC3HDAC6HDAC2CYP24A1 | |
| SCHEMBL12398191 | 0.83 | VDR (0.47) | VDR | |
| SCHEMBL12398156 | 0.82 | VDR (0.48) | VDR | |
| SCHEMBL12398139 | 0.82 | VDR (0.53) | VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016435-A1 | HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES | MCGILL UNIVERSITY (CA) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016435-A1 | HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES | VDR, HDAC3, HDAC4 | VDR 1/4885HDAC3 2/4885HDAC6 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.